Synergy Pharmaceuticals Inc fka SGYPQ

[Methinks]

We are in for a white-knuckle ride. With Canada importing Trulance, recently and more products being developed -

Synergy Pharmaceuticals Inc. (SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced three abstracts that will be presented at Digestive Disease Week (DDW) in Washington D.C. June 2-5, 2018. The presentations include a late-breaking clinical science abstract revealing novel findings from the first study to evaluate uroguanylin response levels in healthy subjects compared to patients with chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Additional poster presentations will highlight a new retrospective risk/benefit analysis of TRULANCE® (plecanatide) and linaclotide for the treatment of adults with CIC, as well as long-term safety and effectiveness data for TRULANCE in IBS-C patients -

I must be cautiously optimistic.